Best Agrolife Ltd
Best Agrolife (formerly known as Sahyog Multibase Limited) [1] is a leading agrochemicals manufacturer in India and is among the top 15 agrochemicals companies in the country. It is one of the fastest growing manufacturers of Technicals, Formulations, Intermediates and Public Health products. Best Agrochem Private Limited was amalgamated with the Co. in April 2018.
It offers more than 70 Formulations in the form of Insecticides, Herbicides, Fungicides and Plant Growth Regulators, which are developed from active ingredients manufactured in-house. As part of its P2P set-up, Best Agrolife caters to several blue-chip corporates and leading MNCs from India and abroad. [2]
- Market Cap ₹ 2,404 Cr.
- Current Price ₹ 1,014
- High / Low ₹ 1,775 / 752
- Stock P/E 10.1
- Book Value ₹ 209
- Dividend Yield 0.20 %
- ROCE 40.7 %
- ROE 45.4 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Promoter holding has increased by 0.90% over last quarter.
Cons
- Company might be capitalizing the interest cost
- Working capital days have increased from 80.1 days to 117 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|
127 | 151 | 905 | 1,211 | 1,801 | |
126 | 154 | 854 | 1,045 | 1,432 | |
Operating Profit | 1 | -2 | 51 | 166 | 369 |
OPM % | 0% | -1% | 6% | 14% | 20% |
1 | 4 | 7 | 2 | 3 | |
Interest | 1 | 2 | 5 | 15 | 33 |
Depreciation | 0 | 0 | 3 | 12 | 24 |
Profit before tax | 0 | 0 | 51 | 141 | 314 |
Tax % | 575% | 100% | 27% | 26% | |
Net Profit | -0 | 0 | 37 | 105 | 239 |
EPS in Rs | -0.65 | 0.03 | 16.83 | 44.31 | 100.96 |
Dividend Payout % | 0% | 798% | 12% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 57% |
3 Years: | % |
TTM: | 62% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 250% |
3 Years: | % |
TTM: | 160% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 229% |
3 Years: | 77% |
1 Year: | 12% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 45% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|
8 | 8 | 22 | 24 | 24 | |
Reserves | 46 | 48 | 108 | 306 | 472 |
0 | 19 | 33 | 270 | 473 | |
63 | 35 | 209 | 384 | 612 | |
Total Liabilities | 117 | 110 | 372 | 984 | 1,580 |
0 | 0 | 19 | 180 | 178 | |
CWIP | 0 | 0 | 4 | 5 | 6 |
Investments | 32 | 3 | 0 | 0 | 0 |
85 | 107 | 349 | 800 | 1,396 | |
Total Assets | 117 | 110 | 372 | 984 | 1,580 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|
-14 | -41 | 13 | -78 | |
-34 | 31 | 8 | 3 | |
48 | 10 | -11 | 67 | |
Net Cash Flow | 0 | -0 | 10 | -8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|
Debtor Days | 85 | 87 | 53 | 77 |
Inventory Days | 67 | 199 | ||
Days Payable | 72 | 124 | ||
Cash Conversion Cycle | 85 | 87 | 48 | 152 |
Working Capital Days | 61 | 175 | 43 | 117 |
ROCE % | 0% | 41% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
16 Mar - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Outcome of Investors/Analysts Meet
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 7 Mar
-
Announcement Under Regulation 30
6 Mar - Approved Capex plan of Rupees 200 crore
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 3 Mar
-
Intimation Under Regulation 30(5) Of SEBI (LODR) Regulations, 2015
1 Mar - Authorizing Key Managerial Personnel of the Company to determining materiality of an event or information and for the purpose of making disclosure to the stock …
Annual reports
Concalls
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Sep 2020TranscriptNotesPPT
Product Portfolio
The Co has three business activities namely, Technical, Formulation, and Branded Products. [1]
The Co has almost 70+ products, 91+ technical licenses, 396+ formulation licenses. [2] [3]
Some of its best selling products are DIRON, PYMAX, PYDON, IRMA, etc. [4]
It launched key products like RONFEN, AXEMAN, REVEAL, CITIGEN, and VISTARA. [5]
It currently has 28 New products under pipeline. [1]